中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 6
Jun.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(6): 1332-1339

Clinical features of hypopituitarism with nonalcoholic fatty liver disease after sellar tumor surgery in children

DOI: 10.3969/j.issn.1001-5256.2023.06.013

  • Department of Genetic Metabolism and Endocrinology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430015, China

Research funding:

China International Medical Foundation (Z-2019-41-2101-01)

More Information
  • Corresponding author: YAO Hui, yaohui1024@sina.com (ORCID: 0000-0002-1878-0012)
  • Received Date: 2022-10-17
  • Accepted Date: 2022-11-20
  • Published Date: 2023-06-20
    Abstract
  •   Objective  To investigate the clinical features of hypopituitarism with nonalcoholic fatty liver disease (NAFLD) in children after sellar tumor surgery and the association between hypopitarism and NAFLD in children.  Methods  A retrospective analysis was performed for the clinical data of children with hypopituitarism and NAFLD after sellar tumor surgery who were followed up regularly in Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, from January 2017 to December 2021, and their clinical features were analyzed.  Results  There were 32 children with regular follow-up and complete clinical data after sellar tumor surgery, and 10 children (31.25%) developed NAFLD, among whom there were 5 boys and 5 girls. Among these 10 children, 9 had craniopharyngioma and underwent surgical treatment, and 1 had germinoma and underwent local radiotherapy. The 10 children had a median age of 8.4(6.29.8) years at the diagnosis of hypopituitarism and a median age of 11.9(8.7-12.6) years at the diagnosis of NAFLD. The median number of years from the diagnosis of hypopituitarism to the diagnosis of NAFLD was 2.0(1.4-4.0) years. At the diagnosis of NAFLD, all 10 children had obesity, and body mass index (BMI) was increased by 7.26±4.25 kg/m2 on average since the diagnosis of hypopituitarism; the 10 children had a mean fasting blood glucose level of 4.67±0.55 mmol/L, a mean fasting insulin level of 25.40±5.93 μIU/ml, and a mean HOMA-IR index of 5.26±1.29. Among these 10 children, 9 had hypertriglyceridemia, and 1 had elevated triglyceride, with a mean level of 3.08±1.09 mmol/L; 6 children had hypercholesterolemia, with a mean level of 5.67±1.25 mmol/L; 8 children had high-density lipoprotein cholesterolemia, with a mean level of 3.97±1.27 mmol/L. After the diagnosis of NAFLD, 2 children were treated with recombinant human growth hormone and metformin and achieved reductions in BMI, HOMA-IR, and triglyceride after treatment, and total cholesterol and low-density lipoprotein cholesterol were reduced to the normal range.  Conclusion  Children may experience weight gain, hypopituitarism, insulin resistance, and dyslipidemia after sellar tumor surgery, which may lead to the onset of NAFLD. Weight management and active pituitary hormone replacement therapy are recommended for such children, as well as routine screening and management of fatty liver disease.

     

    • FullText(HTML)
  • loading
    • References(30)
  • [1]
    HONG JW, KIM JY, KIM YE, et al. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men[J]. Horm Metab Res, 2011, 43(1): 48-54. DOI: 10.1055/s-0030-1265217.
    [2]
    KANG SJ, KWON A, JUNG MK, et al. High prevalence of nonalcoholic fatty liver disease among adolescents and young adults with hypopituitarism due to growth hormone deficiency[J]. Endocr Pract, 2021, 27(11): 1149-1155. DOI: 10.1016/j.eprac.2021.06.003.
    [3]
    HOFFMANN A, BOOTSVELD K, GEBHARDT U, et al. Nonalcoholic fatty liver disease and fatigue in long-term survivors of childhood-onset craniopharyngioma[J]. Eur J Endocrinol, 2015, 173(3): 389-397. DOI: 10.1530/EJE-15-0422.
    [4]
    ADAMS LA, FELDSTEIN A, LINDOR KD, et al. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction[J]. Hepatology, 2004, 39(4): 909-914. DOI: 10.1002/hep.20140.
    [5]
    ALABSAWY E, SERRY Y, KOTHA S, et al. Hepatopulmonary syndrome as the first and only manifestation of cirrhosis in a patient with hypopituitarism[J]. BMJ Case Rep, 2021, 14(9): e244805. DOI: 10.1136/bcr-2021-244805.
    [6]
    MAZERKINA NA, SAVATEEV AN, GORELYSHEV SK, et al. Hepatopulmonary syndrome: a rare manifestation of cirrhosis in patient with diencephalic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma[J]. Probl Endokrinol (Mosk), 2021, 67(5): 58-66. DOI: 10.14341/probl12723.
    [7]
    TORII N, ICHIHARA A, MIZUGUCHI Y, et al. Hormone-replacement therapy for hepatopulmonary syndrome and NASH associated with hypopituitarism[J]. Intern Med, 2018, 57(12): 1741-1745. DOI: 10.2169/internalmedicine.0027-17.
    [8]
    JUNG D, SEO GH, KIM YM, et al. Hepatopulmonary syndrome caused by hypothalamic obesity and nonalcoholic fatty liver disease after surgery for craniopharyngioma: a case report[J]. Ann Pediatr Endocrinol Metab, 2018, 23(1): 51-55. DOI: 10.6065/apem.2018.23.1.51.
    [9]
    JONAS MM, KRAWCZUK LE, KIM HB, et al. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome[J]. Liver Transpl, 2005, 11(1): 108-110. DOI: 10.1002/lt.20332.
    [10]
    JUSTINO H, SANDERS K, MCLIN VA. Rapid progression from hepatopulmonary syndrome to portopulmonary hypertension in an adolescent female with hypopituitarism[J]. J Pediatr Gastroenterol Nutr, 2010, 50(3): 334-336. DOI: 10.1097/MPG.0b013e3181a1c496.
    [11]
    FUJIO A, KAWAGISHI N, ECHIZENYA T, et al. Long-term survival with growth hormone replacement after liver transplantation of pediatric nonalcoholic steatohepatitis complicating acquired hypopituitarism[J]. Tohoku J Exp Med, 2015, 235(1): 61-67. DOI: 10.1620/tjem.235.61.
    [12]
    Subspecialty Group of Endocrine Genetic Metabolism, Society of Pediatrics, Chinese Medical Association; Subspecialty Group of Gastroenterology, Society of Pediatrics, Chinese Medical Association; Professional Committee on Adolescent Medicine, Chinese Pediatric Society, Chinese Medical Association, et al. Expert consensus on the diagnosis and treatment of nonalcoholic fatty liver disease in children[J]. Chin J Pract Pediatr, 2018, 33(7): 487-492. DOI: 10.19538/j.ek2018070602.

    中华医学会儿科学分会内分泌遗传代谢学组, 中华医学会儿科学分会消化学组, 中华医学会儿科学分会青春期医学专业委员会, 等. 儿童非酒精性脂肪肝病诊断与治疗专家共识[J]. 中国实用儿科杂志, 2018, 33(7): 487-492. DOI: 10.19538/j.ek2018070602.
    [13]
    LI H, JI CY, ZONG XN, et al. Body mass index growth carves for Chinese children and adolescents aged 0 to 18 years[J]. Chin J Pediatr, 2009, 47(7): 493-498. DOI: 10.3760/cma.j.issn.0578-1310.2009.07.004.

    李辉, 季成叶, 宗心南, 等. 中国0~18岁儿童、青少年体块指数的生长曲线[J]. 中华儿科杂志, 2009, 47(7): 493-498. DOI: 10.3760/cma.j.issn.0578-1310.2009.07.004.
    [14]
    National Health and Family Planning Commission of the People's Republic of China. WS/T 586-2018 Screening for overweight and obesity in school-age children and adolescent[S]. Beijing: Standards Press of China, 2018.

    中华人民共和国国家卫生和计划生育委员会. WS/T 586-2018学龄儿童青少年超重和肥胖筛查[S]. 北京: 中国标准出版社, 2018.
    [15]
    Subspecialty Group of Insulin Resistance, Chinese Diabetes Society, Chinese Medical Association (in preparation). Expert guidance on methods and application of insulin resistance assessment[J]. Chin J Diabetes Mellitus, 2018, 10(6): 377-385. DOI: 10.3760/cma.j.issn.1674-5809.2018.06.001.

    中华医学会糖尿病学分会胰岛素抵抗学组(筹). 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志, 2018, 10(6): 377-385. DOI: 10.3760/cma.j.issn.1674-5809.2018.06.001.
    [16]
    YIN J, LI M, XU L, et al. Insulin resistance determined by Homeostasis Model Assessment (HOMA) and associations with metabolic syndrome among Chinese children and teenagers[J]. Diabetol Metab Syndr, 2013, 5(1): 71. DOI: 10.1186/1758-5996-5-71.
    [17]
    The Editorial Board, Chinese Journal of Pediatrics; Subspecialty Group of Child Care, Chinese Pediatric Society, Chinese Medical Association; Subspecialty Group of Cardiology, Chinese Pediatric Society, Chinese Medical Association, et al. Expert consensus on the prevention and treatment of dyslipidemia in children and adolescents[J]. Chin J Pediatr, 2009, 47(6): 426-428. DOI: 10.3760/cma.j.issn.0578-1310.2009.06.007.

    《中华儿科杂志》编辑委员会, 中华医学会儿科学分会儿童保健学组, 中华医学会儿科学分会心血管学组, 等. 儿童青少年血脂异常防治专家共识[J]. 中华儿科杂志, 2009, 47(6): 426-428. DOI: 10.3760/cma.j.issn.0578-1310.2009.06.007.
    [18]
    STEFAN N, HÄRING HU, CUSI K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies[J]. Lancet Diabetes Endocrinol, 2019, 7(4): 313-324. DOI: 10.1016/S2213-8587(18)30154-2.
    [19]
    MANN JP, VALENTI L, SCORLETTI E, et al. Nonalcoholic fatty liver disease in children[J]. Semin Liver Dis, 2018, 38(1): 1-13. DOI: 10.1055/s-0038-1627456.
    [20]
    WANG CE, XU WT, GONG J, et al. Research progress in the treatment of nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50(9): 897-899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.

    王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50(9): 897-899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
    [21]
    DU TT, YAO H, LI YK, et al. Hepatopulmonary syndrome after craniopharyngioma operation in children: A case report[J]. J Clin Hepatol, 2022, 38(7): 1620-1625. DOI: 10.3969/j.issn.1001-5256.2022.07.030.

    杜婷婷, 姚辉, 李亚坤, 等. 儿童颅咽管瘤术后出现肝肺综合征1例报告[J]. 临床肝胆病杂志, 2022, 38(7): 1620-1625. DOI: 10.3969/j.issn.1001-5256.2022.07.030.
    [22]
    KHAN MJ, HUMAYUN KN, DONALDSON M, et al. Longitudinal changes in body mass index in children with craniopharyngioma[J]. Horm Res Paediatr, 2014, 82(6): 372-379. DOI: 10.1159/000368798.
    [23]
    HOCHBERG I, HOCHBERG Z. Hypothalamic obesity[J]. Endocr Dev, 2010, 17: 185-196. DOI: 10.1159/000262539.
    [24]
    ABUZZAHAB MJ, ROTH CL, SHOEMAKER AH. Hypothalamic obesity: Prologue and promise[J]. Horm Res Paediatr, 2019, 91(2): 128-136. DOI: 10.1159/000496564.
    [25]
    FUJII H, KAWADA N, JSG-NAFLD JSGON. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease[J]. Int J Mol Sci, 2020, 21(11): 3863. DOI: 10.3390/ijms21113863.
    [26]
    MØLLER N, JØRGENSEN JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects[J]. Endocr Rev, 2009, 30(2): 152-177. DOI: 10.1210/er.2008-0027.
    [27]
    WIJNEN M, van den HEUVEL-EIBRINK MM, JANSSEN J, et al. Very long-term sequelae of craniopharyngioma[J]. Eur J Endocrinol, 2017, 176(6): 755-767. DOI: 10.1530/EJE-17-0044.
    [28]
    HUANG Q, XU H, WANG X, et al. Relationship between growth hormone deficiency and nonalcoholic fatty liver disease in patients with pituitary stalk interruption syndrome[J]. Clin Endocrinol (Oxf), 2022, 97(5): 612-621. DOI: 10.1111/cen.14732.
    [29]
    NISHIZAWA H, IGUCHI G, MURAWAKI A, et al. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy[J]. Eur J Endocrinol, 2012, 167(1): 67-74. DOI: 10.1530/EJE-12-0252.
    [30]
    The Subspecialty Gorup of Endocrinologic, Hereditary and Metabolic Disease, The Society of Pediatrics, Chinese Medical Association; The Editorial Board, Chinese Journal of Pediatrics. Expert consensus on the diagnosis and management of growth hormone deficiency during the transition period[J]. Chin J Pediatr, 2020, 58(6): 455-460. DOI: 10.3760/cma.j.cn112140-20200314-00237.

    中华医学会儿科学分会内分泌遗传代谢学组, 中华儿科杂志编辑委员会. 过渡期生长激素缺乏症诊断及治疗专家共识[J]. 中华儿科杂志, 2020, 58(6): 455-460. DOI: 10.3760/cma.j.cn112140-20200314-00237.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (373) PDF downloads(34) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return